You are here
From patented antibodies to tumour-associated cell surface markers, we have a diverse portfolio of agents from pre-clinical to phase 1 clinical development available for collaborative development and/or licensing.
These three technologies offer a platform of novel CAR-T cell enhancements for improving CAR-T persistence in the tumor microenvironment.Read more
We have developed a first-in-class, therapeutic-quality antibody that inhibits human Arginase-2 and are seeking a partner with interest in arginase in tumour immunosuppression and other areas.Read more
Licensing opportunity around FcɣR-independent “super-agonistic” 4-IBB mABs containing a propriety hinge technology that induces CD8+ T cell activation and intratumoral Treg cell depletion.Read more
We are seeking a partner experienced in the field of cell therapy development and in the Chinese regulatory environment to take this technology through to first in man trials in China.Read more